Click here for: Recently Closed Protocols
Click here for: Upcoming New Protocols
Priority List Updated 7/27/06
(New Protocols in Red)
Protocol Warning: CETUXIMAB/ERBITUX Holiday Closure Information: BMS WILL BE CLOSED ON 4-SEPTEMBER-2006 FOR LABOR DAY. THE LAST SHIPMENT DATE FOR ERBITUX WILL BE 31-AUGUST-2006. BMS WILL RETURN TO THE OFFICE ON TUESDAY, 5-SEPTEMBER-2006 AND PROCESS ORDERS FOR DELIVERIES TO SITES ON WEDNESDAY, 6-SEPTEMBER-2006. Please plan ahead to facilitate realistic treatment start dates for new patients.
Cetuximab/Erbitux Hot Line: 800-743-9224
INDEX
| Brain | Gynecologic | Lymphoma |
| Breast | Head and Neck | Melanoma |
| Gastrointestinal | Leukemia | Myeloma |
| Genitourinary | Lung | Sarcoma and other |
R9813 Consent HIPAA Fast Facts Protocol
A Phase I/III Randomized Study of Radiation Therapy and Temozolomide vs. Radiation Therapy and BCNU for Anaplastic Astrocytoma
NCCTG N0272 Consent Consent 2 HIPAA Protocol (No anticonvulsant)
Phase I/II Trial of Imatinib Mesylate in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
NCCTG N047B Consent1 Consent2 Consent3 HIPAA Protocol
A Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Recurrent Glioblastoma Multiforme
Breast DCIS
Breast - Node Positive
NSABP B-38 Consent HIPAA Fast Facts Protocol
A Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed By DD Paclitaxel (DD AC-- P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC -- PG)
Breast - Node Negative
NSABP B-36 Consent HIPAA Fast Facts Protocol
A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide to Four Cycles of Adriamycin and Cyclophosphamide, With or Without Celecoxib, in patients with Node-Negative Breast Cancer
CTSU CALGB 40101 Consent HIPAA Fast Facts Protocol
Cyclophosphamide and Doxorubicin vs. Paclitaxel as Adjuvant Therapy for Women with Node-Negative Breast Cancer
CTSU CALGB 70301 Consent HIPAA Schema Protocol
Quality of Life, Employment, and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Node-Negative Breast Cancer
CTSU MA.20 Consent HIPAA Protocol
A Phase III Study of Regional Radiation Therapy in Early Breast Cancer
Breast - Node Positive or Negative
SWOG S0221 Consent HIPAA Protocol Antioxidant Use
Phase III Trial of Continuous Schedule AC + G vs. Q-2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Postoperative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer
SWOG S0307 Consent HIPAA Protocol
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
CTSU CALGB 49907 Consent HIPAA Fast Facts Protocol
A Randomized Trial of Adjuvant Chemotherapy With Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil or Doxorubicin and Cyclophosphamide Versus Capecitabine in Women 65 Years and Older With Node Positive or High-Risk Node Negative Breast Cancer
CTSU MA.27 Consent HIPAA Protocol (Must be enrolled in MA.27B & N0434)
A Randomized Phase III Trial of Exemestane vs Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer
CTSU MA.27B Consent HIPAA Protocol Site Accreditation
The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density in Postmenopausal Women with Primary Breast Cancer
CTSU N0434 (MA.27D) Consent HIPAA Fast Facts Protocol
Association of Breast Density Changes, Plasma Hormone Changes and Breast Cancer Recurrence (Companion MA.27D)
NSABP B-39 Consent HIPAA Fast Facts Protocol
A Randomized Phase III Study of Conventional Whole Breast Irradiation versus Partial Breast Irradiation for Women with Stage 0, I or II Breast Cancer
Ovarian Function Failure
SWOG S0230 Consent HIPAA Protocol
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Standard Adjuvant Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Breast - Inflammatory
Breast - Relapse
NSABP B-37 Consent HIPAA Fast Facts Protocol
A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-regional Relapse of Breast Cancer
Breast - Metastatic
SWOG S0215 Consent HIPAA Protocol
Docetaxel and Vinorelbine Plus Filgrastim with Weekly Trastuzumab for HER-2 Positive, Stage IV Breast Cancer
SWOG S0226 Consent HIPAA Protocol
Phase III Randomized Trial of Anastrozole vs. Anastrozole and Fulvestrant as First-Line Therapy for Post Menopausal Women with Metastatic Breast Cancer
SWOG S0430 Consent HIPAA Fast Facts Protocol
A Phase II Trial of Simple Oral Therapy (Continuous Oral Cyclophosphamide and Capecitabine) in Patients with Metastatic Breast Cancer
SWOG S0511 Consent HIPAA Fast Facts Protocol
A Phase II Study of Goserelin Plus Anastrozole as First Line Treatment in Male Patients with Hormone-Receptor Positive Metastatic or Recurrent Breast Cancer
Breast-Other
CTSU PACCT-1 TAILORx Call MCC for Consent HIPAA Fast Facts Protocol
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
IBCSG 24-02 Consent HIPAA Fast Facts Protocol
A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer
IBCSG 25-02 Consent HIPAA Fast Facts Protocol
A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer
Colon - Rectal
CTSU E5202 Consent HIPAA Protocol
A Randomized Phase II Study Comparing 5-FU, Leucovorin and Oxaliplatin vs 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
CTSU N0147 Consent HIPAA Fast Facts Protocol
A Randomized Phase III Trial of Irinotecan and/or Oxaliplatin Plus 5-Fluorouracil/Leucovorin After Curative Resection for Patients with Stage III Colon Cancer
NSABP C-08 Consent HIPAA Fast Facts Protocol
A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin Every Two Weeks with Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients with Resected Stages II and III Carcinoma of the Colon
NSABP C-10 Consent HIPAA Fast Facts Protocol
A Phase II Trial of 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) Chemotherapy plus Bevacizumab for Patients with Unresectable Stage IV Colon Cancer and a Synchronous Asymptomatic Primary Tumor
CTSU CALGB 80405 Consent HIPAA Fast Facts Protocol
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Rectal
NSABP R-04 Consent HIPAA Fast Facts Protocol
A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil in the Treatment of Patients with Operable Carcinoma of the Rectum
CTSU E5204 Consent HIPAA Fast Facts Protocol
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin versus Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation
Stomach
CTSU CALGB 80101 Consent HIPAA Fast Facts Protocol
A Phase III Trial of Adjuvant Chemoradiation After Resection of Gastric and Gastroesophageal Adenocarcinoma
SWOG S0425 Consent HIPAA Fast Facts Protocol
Neoadjuvant Chemoradiation Therapy with Oxaliplatin and Capecitabine for Patients with Surgically Resectable Gastric Cancer: A Pilot Phase II Trial with Molecular Correlates
Esophageal
SWOG S0356 Consent HIPAA Protocol
Oxaliplatin Plus Protracted Infusion 5-Fluorouracil and Radiation for Potentially Curable Esophageal Cancer: A Phase II Trial with Molecular Correlates
SWOG S0414 Consent HIPAA Fast Facts Protocol
Cetuximab Plus Cisplatin Irinotecan and Thoracic Radiotherapy for Locally Advanced (Non-Metastatic), Clinically Unresectable Esophageal Cancer: A Phase II Trial with Molecular Correlates
SWOG S0415 Consent HIPAA Fast Facts Protocol
Cetuximab as a Second Line Therapy in Patients with Metastatic Esophageal Cancer
Pancreas
CTSU E2204 Consent HIPAA Fast Facts Protocol
An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and In Combination with Chemoradiation (Capecitabine and RT) in Patients with Completely-Resected Pancreatic Cancer
Gallbladder
SWOG S0514 Consent HIPAA Fast Facts Protocol (Temporary Closure)
Phase II Study of BAY 43-9006 as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma
Prostate
SWOG 9205 Consent HIPAA Protocol
Central Prostate Cancer Serum Repository Protocol
SWOG 9346 Consent HIPAA Protocol
Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer
SWOG 9917 Consent HIPAA Protocol
L-Selenium-Based Chemoprevention of Prostate Cancer Among Men With High Grade Prostatic Intraepithelial Neoplasia
SWOG 9921 Consent HIPAA Protocol
Adjuvant Androgen Deprivation vs. Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy
CTSU CALGB 90202 Consent HIPAA Fast Facts Protocol
A Randomized, Double-blind, Placebo-controlled Phase III Study of Early vs. Standard Zoledronic Acid to Prevent Skeletal-related Events in Men with Prostate Cancer Metastatic to Bone
CTSU CALGB 90401 Consent HIPAA Fast Facts Protocol
A Randomized, Double-Blinded. Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With and Without Bevacizumab in Men with Hormone Refractory Prostate Cancer
CTSU MDA-3410 Consent HIPAA Fast Facts Protocol
A Prospective Randomized Phase II Trial Comparing Consolidation Therapy With or Without Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer
CTSU RTOG 0415 Consent HIPAA Fast Facts Protocol
A Phase III Randomized Study of Hypofractinated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer
CTSU RTOG 0521 Consent HIPAA Fast Facts Protocol
A Phase III Protocol of Androgen Suppression (AS) and Radiotherapy (RT) vs AS and RT Followed by Chemotherapy with Doxetaxel and Prednisone for Localized High-Risk Prostate Cancer
Bladder/Urothelium
SWOG S0028 Consent HIPAA Fast Facts Protocol
Protocol for Assessment of Gemcitabine and Paclitaxel for Metastatic Urothelial Cancer in Patients Aged 70 Years or Older (and in a Cohort of Patients Younger Than 60 Years), Phase II & Pharmacology
SWOG S0306 Consent HIPAA Fast Facts Protocol
A Phase II Study of Irinotecan in Patients with Advanced Transitional Cell Carcinoma of the Urothelium
SWOG S0219 Consent HIPAA Fast Facts Protocol
A Sequential Approach to the Treatment of Muscle Invasive, Non-Metastatic Carcinoma of the Bladder: A Phase II Trial of Neoadjuvant Gemcitabine, Paclitaxel and Carboplatin with Molecular Correlates
Germ Cell Malignancies
none
Renal
CTSU E2805 Call MCC for Consent HIPAA Fast Facts Protocol
A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
CTSU E8802 Consent HIPAA Fast Facts Protocol
Phase II Trial of Doxorubicin and Gemcitabine in Metastatic Renal Cell Carcinoma with Sarcomatoid Features
Ovarian
CTSU GOG 0198 Consent HIPAA Fast Facts Protocol
A Randomized Study of Tamoxifen vs. Thalidomide in Patients with Biochemical Recurrence-only Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma After First-line Chemotherapy
CTSU GOG 0218 Consent HIPAA Fast Facts Protocol
A Phase III Trial of Carboplatin and Paclitaxil plus Placebo versus Carboplatin and Paclitaxil plus Concurrent Bevacizumab followed by Placebo versus Carboplatin and Paclitaxil plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated Suboptimal Advanced Stage Epithelial Ovarian and Primary Peritoneal Cancer
Cervical
CTSU GOG0219 Consent HIPAA Fast Facts Protocol
A Phase III Randomized Trial of Weekly Cisplatin and Radiotherapy versus Cisplatin and Tirapazamine and Radiotherapy in Stage IB2, IIA, IIIB, and IVA Cervical Cancer Limited to the Pelvis
Endometrial
CTSU GOG 0209 Consent HIPAA Fast Facts Protocol
Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF vs. Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer
CTSU E1302 Consent HIPAA Fast Facts Protocol
Phase III Randomized, Placebo-Controlled Trial of Docetaxel Versus Docetaxel Plus ZD1839(Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients with Recurrent or Metastatic Head and Neck Cancer
CTSU E1303 Consent HIPAA Fast Facts Protocol (Temporary Closure)
Phase II Trial of PS-341 (NSC-681239) Followed by the Addition of Doxorubicin at Progression in Advanced Cystic Carcinoma of the Head and Neck
SWOG S0329 Consent HIPAA Protocol
Phase II Study of Biweekly Gemcitabine and Paclitaxel Combination in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
SWOG S0427 Consent HIPAA Protocol
A Phase III Trial of Standard Fractionation Radiation and Concurrent Fluorouracil Induction Chemotherapy in Patients with Advanced Oropharyngeal Squamous Cell Cancer
SWOG S0431 Consent HIPAA Protocol
A Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland Carcinoma
SWOG S0618 Consent HIPAA Fast Facts Protocol
Phase II Evaluation of E7389 in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
CTSU RTOG 0421 Consent HIPAA Fast Facts Protocol
A Phase III Trial for Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Re-Irradiation and Chemotherapy Versus Chemotherapy Alone
CTSU RTOG 0522 Consent HIPAA Fast Facts Protocol PET Requirements and Credentialing
A Phase III Trial of Concurrent Accelerated Radiation and Chemotherapy vs Concurrent Accelerated Radiation, Chemotherapy and Cetuximab (C225) for Stage III and IV Head and Neck Carcinoma
Salivary Gland
SWOG S0431 Consent HIPAA Protocol
Phase II Study of Trastuzumab in Advanced High Grade Salivary Gland Carcinoma
Acute Leukemia
SWOG 9007 Consent HIPAA Protocol
Cytogenetics Studies in Leukemia Patients, Ancillary
SWOG 9910 Consent HIPAA Protocol
Leukemia Centralized Reference Laboratories and Tissue Repositories Consent to Perform Cellular and Molecular Studies in Leukemia Patients
SWOG S0106 Consent HIPAA Protocol
A Phase III Study of the Addition of Gemtuzumab Ozogamicin During Induction Therapy vs. Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemruzumab Ozogamicin or No Additional Therapy for Patients Under Age 56 with Previously Untreated De Novo Acute Myeloid Leukemia
SWOG S0301 Consent HIPAA Protocol
A Phase II Study of Induction with Daunorubicin, Cytarabine, and Cyclosporine All by Continuous IV Infusion for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older
SWOG S0605 Consent HIPAA Protocol
A Phase II Study of Lenalidomide (Revlimid) (NSC-703813) for Previously Untreated Non-M3 Deletion 5Q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy
CTSU CALGB 10201 Consent HIPAA Fast Facts Protocol
A Phase III Study of Daunorubicin and Cytarabine + G3139, a BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients with Acute Myeloid Leukemia > 60 Years
CTSU E2902 Consent HIPAA Fast Facts Protocol
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Induction Failure
CTSU E1900 Call MCC to request consent HIPAA Fast Facts Protocol
A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification and Gentuzumab-Ozogamicin Consolidation Therapy Prior to Autologous Stem Cell Transplantation Study
Chronic Leukemia
SWOG S0325 Consent HIPAA Protocol
A Phase IIb Study of Molecular Responses to Imatinib at Standard or Increased Doses for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase
Lymphoblastic Leukemia
SWOG S0333 Consent HIPAA Protocol
A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy
SWOG C10001 Consent-R Consent-D HIPAA Fast Facts Protocol
A Phase II Trial of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, STI571) and Transplantation for Adults with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia
SWOG 9925 Protocol (NO CONSENT)
Lung Cancer Specimen Repository Protocol, Ancillary
Non-Small Cell
SWOG 0229 Consent HIPAA Protocol
A Randomized Trial Assessing the Effects of Exercise on Patients with Locally-Advanced Non-Small Cell Lung Cancer Undergoing Curative-Intent Combined Modality Therapy (Ancillary to S0023)
SWOG S0220 Consent HIPAA Fast Facts Protocol
A Phase II Trial of Induction Chemoradiotherapy with Cisplatin/Etoposide Followed by Surgical Resection, Followed by Docetaxel, for Non-Small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors)
SWOG S0424 Consent HIPAA Fast Facts Protocol
Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men
SWOG S0429 Consent HIPAA Fast Facts Protocol
A Pilot (Phase I) Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor RiskStage III Non-Small Cell Lung Cancer
SWOG E5597 Consent HIPAA Protocol
Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer
NCCTG N0422 Consent HIPAA Protocol
Cetuximab and Radiation in Elderly and/or Poor Performance Status Patients with Locally Advanced Non-Small Cell Lung Cancer: A Phase II Study to Evaluate Survival and Toxicity
NCCTG N0426 Consent HIPAA Protocol
A Phase II Study of Pemtrexed Disodium (Alimta) Plus Bevacizumab in Patients with Stage IIIB Pleural Effusion or Stage IV Non-Small Cell Lung Cancer (Second-line Treatment)
RTOG 0214 Consent HIPAA Fast Facts Protocol
Phase III Comparison of Prophylactic Cranial Irradiation vs. Observation in Patients with Locally Advanced Non-Small Cell Lung Cancer
CTSU E3598 Consent HIPAA Fast Facts Protocol
A Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, With or Without Thalidomide in Patients with Stage III NSCLC
NCCTG N0323 Consent HIPAA Protocol
A Phase II Study of the mTOR Inhibitor, CCI-779 in Patients with Advanced Non-Small Cell Lung Cancer
CTSU RTOG 0412 Consent HIPAA Fast Facts Protocol
Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients with Stage IIIA Non-Small Cell Lung Cancer
Small Cell
SWOG S0124 Consent HIPAA Fast Facts Protocol
Randomized Phase III Trial of Cisplatin and Irinotecan vs. Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer
SWOG S0222 Consent HIPAA Fast Facts Protocol
A Phase II Study of Tirapazamine/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
SWOG S0435 Consent HIPAA Protocol
A Phase II Trial of BAY 43-9600 in Patients with Platinum-Treated Extensive Stage Small Cell Lung Cancer (Platinum-sensitive Stratum - temporary closure)
Lung-Other
SWOG S0509 Consent HIPAA Fast Facts Protocol
A Phase II Trial of Novel Oral Anti-angiogenic Agent AZD2171 in Malignant Pleural Mesothelioma
SWOG 8819 (NO CONSENT) Protocol
Central Lymphoma Repository Tissue Procurement
SWOG 8947 Consent HIPAA Protocol
Central Lymphoma Serum Repository
SWOG 9245 Consent HIPAA Protocol
Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease
Hodgkin's
SWOG S0517 Consent HIPAA Fast Facts Protocol
A Phase II Trial of Suberoylanilide Hydroxamic Acid For Recurrent or Primary Refractory Hodgkin's Lymphoma
Non-Hodgkin's
SWOG 9704 Consent HIPAA Fast Facts Protocol
A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy (With Possible Late Autologous Stem Cell Transplant) for Patients With Diffuse Aggressive Non-Hodgkin’s Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups
SWOG
S0016
A Phase III
Trial of CHOP vs. CHOP + Rituximab vs. CHOP + Iodine 131 Labeled
SWOG S0350 Consent HIPAA Fast Facts Protocol
Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol in Peripheral T-cell Non-Hodgkin's Lymphoma
SWOG S0433 Consent HIPAA Fast Facts Protocol
Iodine-131-Labeled Monoclonal Anti-B1 Antibody in Combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab Therapy for Patients Greater Than or Equal to Age 60 with Advanced Stage Diffuse Large B-Cell NHL
SWOG S0515 Consent HIPAA Fast Facts Protocol
Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell NHL
SWOG S0520 Consent HIPAA Fast Facts Protocol
Phase II Study of PXD101 in Relapsed and Refractory Aggressive B-Cell Lymphomas
SWOG C50201 Consent HIPAA Fast Facts Protocol
A Phase II Study to Evaluate the Safety and Efficacy of Zevalin (IND# BBIND11023) Therapeutic Regimen in Patients with Transformed CD20+ B-cell Non-Hodgkins Lymphoma
CTSU E 4402 Consent HIPAA Fast Facts Protocol
A Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Patients with Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
CTSU CALGB 50303 Consent HIPAA Fast Facts Protocol
Randomized Study of R-CHOP versus Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated DeNovo Diffuse Large B-Cell Lymphomas
Mantle Cell
SWOG S0213 Consent HIPAA Protocol
Pilot Trial of Hyper-CVAD and Methotrexate/Ara-C + Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma
NCCTG N038H Consent HIPAA Protocol
A Phase II Study of CCI-779 in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma
SWOG
S0008
Phase III Trial of High
Dose Interferon Alpha-2b Versus Cisplatin, Vinblastine,
SWOG S0508 Consent HIPAA Fast Facts Protocol
A Phase II Trial of Combination Thalidomide plus Temozolomide in Patients with Metastatic Malignant Melanoma
SWOG S0512 Consent HIPAA Protocol
Phase II Trial of BAY 43-9006(Sorafenib) in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma
CTSU E2603 Consent HIPAA Fast Facts Protocol
A Double-blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma
SWOG E4697 Consent HIPAA Protocol
A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF vs. Peptide Vaccination vs. GM-CSF Plus Peptide Vaccination vs. Placebo in Patients with No Evidence of Disease after Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma
SWOG S0115 Consent HIPAA Protocol
Phase II Trial Evaluating Modified High Dose Melphalan and Autologous Peripheral Blood Stem Cell Supported Transplantation for High Risk Patients with Multiple Myeloma and/or Light Chain Amyloidosis
SWOG S0120 Consent HIPAA Fast Facts Protocol
A Prospective Observational Biologic Study of Asymptomatic Patients With Monoclonal Gammopathy and Plasma Proliferative Disorders
SWOG S0232 Consent HIPAA Protocol
Double-Blinded Placebo Controlled Phase III Trial Comparing Dexamethasone to the Combination of Dexamethasone + CC-5013 in Patients with Newly Diagnosed Multiple Myeloma
SWOG S0309 (No Consent) HIPAA Protocol
Myeloma Specimen Repository Protocol, Ancillary
SWOG E1A02 Consent HIPAA Protocol
Phase II Pilot Study of Ribuximab + CHOP in Patients with Newly Diagnosed Waldenstrom's Macroglobulinemia
SWOG S0334 Consent HIPAA Protocol
Cytogenetic and Fluorescence In-Situ Hybridization Studies in Multiple Myeloma
SWOG S0340 Consent HIPAA Protocol
A Prospective Observational Study of Patients with Solitary Plasmacytoma Using a Modified Staging System Supplemented by an MRI and Whole Body FDG-PET Scan
SWOG S0417 Consent HIPAA Protocol
A Phase II Study of Bortezomib (Velcade), Thalidomide, Dexamethasone in Patients with Refractory Multiple Myeloma
SWOG S0434 Consent HIPAA Protocol
A Phase II Trial of BAY 43-9006 (Sorafenib) in Patients with Relapsing or Resistant Multiple Myeloma Previously Treated with Bortezomib
SWOG S0345 Consent HIPAA Fast Facts Protocol
A Phase II Study of Imatinib in Patients with Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans
SWOG S0346 Consent HIPAA Protocol
Phase II Study of Trastuzumab in Treatment of Locally Advanced or Metastatic Synovial Sarcoma
SWOG S0423 Consent HIPAA Fast Facts Protocol
Phase II Trial of Pemetrexed for Advanced Chondrosarcomas
SWOG S0505 Consent HIPAA Protocol
A Phase II Trial of BAY 43-9006 (Sorafenib) in Advanced Soft Tissue Sarcomas
Other
SWOG S0331 Consent HIPAA Fast Facts Protocol
A Phase II Trial of STI-571/Imatinab in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)
SWOG S0346 Consent HIPAA Protocol
Phase II Study of Trastuzumab (NSC-688097) in Treatment of Locally Advanced or Metastatic Synovial Sarcoma
NCCTG N004E Consent Consent 2 HIPAA Protocol
Phase II Study of Gemcitabine (Gemzar) and Irintecan (CPT-11) in Previously Untreated Patients with Measurable Disease with Unknown Primary Carcinoma